Although the morbidity and mortality rates of prostate cancer (PCa) are considerably high, many PCas are characterized as indolent and slow growing, which do not require overtreatment. Overdiagnosis and overtreatment of early detected PCa are an emerging problem, owing to a lack of biomarkers that detect advanced disease at an earlier stage. In this study, RNA-Seq data of 57,045 genes for 495 PCa samples and 52 normal samples in the The Cancer Genome Atlas (TCGA) database were downloaded. Subsequently, we performed weighted gene coexpression network analysis to identify the Gleason score-related coexpression gene module, and further screened out oncogenes and tumor suppressors that were upregulated or downregulated in the early stage of PCa as well as those related to the clinical prognosis of PCa patients. Based on this study, some novel biomarkers were identified for the disease-free survival, which are helpful for fast diagnosis and prognosis.
Get full access to this article
View all access options for this article.
References
1.
BatsonJ., Maccarthy-MorroghL., ArcherA., TantonH., and NobesC.D. (2014). EphA receptors regulate prostate cancer cell dissemination through Vav2-RhoA mediated cell-cell repulsion. Biol Open, 3, 453–462.
2.
BrayF., FerlayJ., SoerjomataramI., SiegelR.L., TorreL.A., and JemalA. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394–424.
3.
BusàR., ParonettoM.P., FariniD., PierantozziE., BottiF., AngeliniD.F., et al. (2007). The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene, 26, 4372–4382.
4.
CaoS., YanB., LuY., ZhangG., LiJ., ZhaiW., et al. (2015). Methylation of promoter and expression silencing of GPX3 gene in hepatocellular carcinoma tissue. Clin Res Hepatol Gastroenterol, 39, 198–204.
5.
CeramiE., GaoJ., DogrusozU., GrossB.N., SumerS.O., AksoyB.A., et al. (2012). The CBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data cancer discovery. 2, 401–404.
6.
CuiY., NadimintyN., LiuC., LouW., SchwartzC.T., and GaoA.C. (2014). Upregulation of glucose metabolism by NF-KB2/P52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr Relat Cancer, 21, 435–442.
7.
DiaoY., WuD., DaiZ., KangH., WangZ., and WangX. (2015). Prognostic value of transformer 2β expression in prostate cancer. Int J Clin Exp Pathol, 8, 6967–6973.
8.
GaoJ., AksoyB.A., DogrusozU., DresdnerG., GrossB., SumerS.O., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the CBioPortal. Sci Signal 6,pl1.
9.
GeX., WangX., and ShenP. (2013). Herpes simplex virus type 2 or human herpesvirus 8 infection and prostate cancer risk: a meta-analysis. Biomed Rep, 1, 433–439.
10.
GyörffyB., LanczkyA., EklundA.C., DenkertC., BudcziesJ., LiQ., et al. (2010). An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat, 123, 725–731.
11.
HaudenschildD., MoseleyT., RoseL., and ReddiA. (2002). Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J Biol Chem, 277, 4309–4316.
12.
HavelL.S., KlineE.R., SalgueiroA,M., and MarcusA.I. (2015). Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity. Oncogene, 34, 1979–1990.
13.
HeZ., ChenH., LiG., ZhuH., GaoY., ZhangL., et al. (2014). Diosgenin inhibits the migration of human breast cancer MDA-MB-231 cells by suppressing Vav2 activity. Phytomedicine, 21, 871–876.
14.
HuJ., and ChenQ. (2017). The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside. Int Urol Nephrol, 49, 369–380.
15.
JemalA., BrayF., CenterM.M., FerlayJ., WardE., and FormanD.2011. Global cancer statistics. CA Cancer J Clin, 61, 69–90.
16.
JianL., XieL.P., LeeA.H., and BinnsC.W. (2004). Protective effect of green tea against prostate cancer: a case-control study in Southeast China. Int J Cancer, 108, 130–135.
17.
KamangarF., DoresG.M., and AndersonW.F. (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137–2150.
18.
LangfelderP., and HorvathS. (2008). WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9,559.
19.
LiY., AlsagabiM., FanD., BovaG.S., TewfikA.H., and DehmS.M. (2011). Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res, 71, 2108–2117.
20.
MunkleyJ., LivermoreK.L., RajanP., and ElliottD.J. (2017). RNA splicing and splicing regulator changes in prostate cancer pathology. Hum Genet, 136, 1143–1154.
21.
NadimintyN., TummalaR., LiuC., LouW., EvansC.P., and GaoA.C. (2015). NF-KB2/P52:C-Myc:HnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. Mol Cancer Ther, 14, 1884–1895.
22.
PeterL., and HorvathS. (2012). Fast R functions for robust correlations and hierarchical clustering. J Stat Softw, 46, 1–17.
23.
RenS., ChenR., and SunY.-H. (2013). Prostate cancer research in China. Asian J Androl, 15, 350–353.
24.
RyuS., LimW., BazerF.W., SongG. (2017). Chrysin induces death of prostate cancer cells by inducing ROS and ER stress. J Cell Physiol, 232, 3786–3797.
25.
SbonerA., DemichelisF., CalzaS., PawitanY., SetlurS.R., HoshidaY., et al. (2010). Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 3,8.
26.
SegawaT., NauM.E., XuL.L., ChilukuriR.N., MakaremM., ZhangW., et al. (2002). Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene, 21, 8749–8758.
27.
ShannonP., MarkielA., OzierW., BaligaN.S., WangJ.T., RamageD., et al. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 13, 2498–2504.
28.
TaylorB.S., SchultzN., HieronymusH., GopalanA., XiaoY., CarverB.S., et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell, 18, 11–22.
29.
ThorneH., WillemsA.J., NiedermayrE., HohI.M.Y., LiJ., CloustonD., et al. (2011). Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila), 4, 1002–1010.
30.
WolfH., MadsenP.O., and PriceJ.M. (1968). Studies on the metabolism of tryptophan in patients with benign prostatic hypertrophy or cancer of the prostate. J Urol, 100, 537–543.
31.
YeD., and ZhuY. (2015). [Epidemiology of prostate cancer in China: an overview and clinical implication]. Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery], 53, 249–252.
32.
YuY.P., YuG., TsengG., CieplyK., NelsonJ., DefrancesM., et al. (2007). Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res, 67, 8043–8050.
33.
ZayzafoonM., AbdulkadirS.A., and McDonaldJ.M. (2004). Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem, 279, 3662–3670.
34.
ZhaoH., LiJ., LiX., HanC., ZhangY., ZhengL., et al. (2015). Silencing GPX3 expression promotes tumor metastasis in human thyroid cancer. Curr Protein Pept Sci, 16, 316–321.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
